Management of the febrile neutropenic cancer patient: Lessons from 40 years of study

Clinical Microbiology and Infection, Supplement

Volumn 11, Issue 5, 2005, Pages 24-29

  Bow, E J ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cancer; Febrile neutropenic episodes; Natural history; Neutropenia; Pathogenesis; Prophylaxis; Review; Risk factors

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VINCRISTINE;

ALGORITHM; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION RISK; LEUKOCYTE COUNT; MORBIDITY; MORTALITY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

EID: 25144525642     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01240.x     Document Type: Review

References (77)

1. Garcia-Rodriguez JA, Gobernado M, Gomis M et al. Clinical guide for the evaluation and treatment of patients with neutropenia and fever. Rev Esp Quimioter 2001; 14(1): 75-83.
2. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34(6): 730-751.
3. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(suppl 2): S105-S117.
4. Freifeld AG, Brown AE, Elting L et al. Fever and neutropenia. J National Comprehensive Cancer Network 2005; 2(5): 390-432.
5. Bodey GP. The treatment of febrile neutropenia: from the Dark Ages to the present. Support Care Cancer 1997; 5(5): 351-357.
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64(2): 328-340.
7. Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients. a study of 494 consecutive patients. Cancer 1978; 41 (4): 1610-22.
8. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061-1065.
9. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77(5): 707-714.
10. Pizzo PA, Robichaud KJ, Gill FA et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67(2): 194-200.
11. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72(1): 101-111.
12. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2(4): 231-242.
13. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326(7399): 1111-1120.
14. Vamvakas EC, Pineda AA. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 1996; 11: 1-9.
15. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 1997; 12: 74-81.
16. Schiffer CA. Granulocyte transfusion therapy. Curr Opin Hematol 1999; 6: 3-7.
17. Berghmans T, Paesmans M, Lafitte JJ et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10(3): 181-188.
18. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957-1960.
19. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23(4): 795-805.
20. Rotstein C, Mandell L, Goldberg N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Oncol 1997; 4(suppl 2): S2-S7.
21. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16(3): 1179-1187.
22. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21(22): 4127-4137.
23. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against infection in neutropenic patients - a meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
24. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94(12): 3230-3246.
25. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21(24): 4615-4626.
26. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38(2): 161-189.
27. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4): 696-709.
28. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.
29. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18(16): 3038-3051.
30. Rolston KV, Talcott JA. Ambulatory antimicrobial therapy for hematologic malignancies. Oncology (Huntingt) 2000; 14(8 suppl 6): 17-22.
31. Talcott JA. Out-patient management of febrile neutropenia. Int J Antimicrob Agents 2000; 16(2): 169-171.
32. Bow EJ. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: history, background and approaches to management. In: Wingard JR, Bowden RA, eds. Management of infection in oncology patients. London: Martin Dunitz, 2003; 71-104.
33. Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995; 20(4): 907-912.
34. Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003; 36(2): 149-158.
35. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19(8): 2201-2205.
36. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997; 15(6): 2254-2261.
37. Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110(2): 292-299.
38. Meropol NJ, Somer RA, Gutheil J et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21(8): 1452-1458.
39. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397-401.
40. Peacock JE, Herrington DA, Wade JC et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002; 137(2): 77-87.
41. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998; 41(suppl D): 1-5.
42. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-351.
43. Maher DW, Lieschke GJ, Green M et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia - a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121(7): 492-501.
44. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32(3): 391-395.
45. Doorduijn JK, van der Holt B, van Imhoff GW et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21(16): 3041-3050.
46. Hagen EA, Stern H, Porter D et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36(1): 9-15.
47. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma 1. Cancer 2003; 98(11): 2402-2409.
48. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy 1. Leuk Lymphoma 2003; 44(12): 2069-2076.
49. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices 1. J Clin Oncol 2003; 21(24): 4524-4531.
50. Paesmans M. Risk factors assessment in fabrile neutropenia. Int J Antimicrob Agents 2000; 16(2): 107-111.
51. Talcott JA. Out-patient management of febrile neutropenia. Int J Antimicrob Agents 2000; 16(2): 169-171.
52. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12(1): 107-114.
53. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10(2): 316-322.
54. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148(12): 2561-2568.
55. Kern WV. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 2001; 14(4): 415-422.
56. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992; 339(8801): 1092-1096.
57. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341(5): 305-311.
58. Kern WV, Cometta A, de Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341(5): 312-318.
59. Cornely OA, Wicke T, Seifert H et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004; 79(1): 74-78.
60. Rubenstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71(11): 3640-3646.
61. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000; 34(2): 87-91.
62. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86(1): 126-134.
63. Minotti V, Gentile G, Bucaneve G, Tanaka C, Ginani VC, Seber A. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999; 7(3): 134-139.
64. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991; 2(7): 485-487.
65. Hidalgo M, Hornedo J, Lumbreras C et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. Cancer 1999; 85(1): 213-219.
66. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98(3): 224-231.
67. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120(10): 834-844.
68. Cometta. A, Zinner S, De Bock R et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39(2): 445-452.
69. Bow EJ, Noskin GA, Schwarer AP, Laverdiere M, Vesole DH. Efficacy of piperacillin/tazobactam as initial empiric therapy for febrile neutropenia in patients with hematological malignancy [abstract 1000]. Blood 2003; 102(11): 281a.
70. Viscoli C. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002; 38(suppl 4): S82-S87.
71. Wade JC, Glasmacher A. Vancomycin does not benefit persistently febrile neutropenic people with cancer. Cancer Treat Rev 2004; 30(1): 119-126.
72. Bow EJ, Loewen R, Vaughn D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995; 20: 907-912.
73. Bow EJ, Mandell LA, Louie TJ et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125(3): 183-190.
74. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29(3): 490-494.
75. EORTC International Antimicrobial Therapy Cooperative Project Group, National Cancer Institute of Canada - Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients. J Infect Dis 1991; 163: 951-958.
76. de Marie S, van den Broek PJ, Willemze R, van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 1993; 12(12): 897-906.
77. Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12(5): 1005-1011.